… the risk of venous thromboembolism (VTE) in cancer patients … In summary, the results of the
Hokusai VTE Cancer and … randomized to edoxaban or dalteparin, patients were excluded if …

… HOKUSAI-Cancer study, which showed that edoxaban is … Trial Investigators. Long-term
low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer…

… RCTs that reported recurrent venous thromboembolism (VTE) … ; 2 for edoxaban; and 1 for
apixaban); 35,142 patients (8,855 … RCTs, including latest Hokusai VTE Cancer trial, reported a …

… well as venous thromboembolism (VTE) including deep vein … , edoxaban and rivaroxaban
may be used in cancer patients. Due to scarce data, do not use of dabigatrin in cancer patients…

… Hokusai-VTE Cancer trial have been recently published (Fig. 15.2). This study has demonstrated
that oral edoxaban … venous thromboembolism or major bleeding. The rate of recurrent …

… of active cancer patients with venous thromboembolism and high … in patients with GI tumors
in the Hokusai VTE Cancer and … adjustment to edoxaban 30 mg once daily for patients taking …

… the treatment of non-cancer venous thromboembolism (VTE) … The Hokusai-VTE cancer trial
randomized 1046 participants … As observed in the trial of edoxaban, GI major bleeding was …

… , including edoxaban (Hokusai VTE Cancer [Edoxaban for the … the skin were not included in
the Hokusai VTE Cancer trial. … of recurrent venous thromboembolism in patients with cancer (…

… ISTH and ASCO include both rivaroxaban and edoxaban as options for treatment of
cancer-associated VTE, along with LMWH. As these two guidelines were updated prior to the …

… research network screened their ambulatory patients for adults with a new diagnosis of venous
thromboembolism … were significantly higher for edoxaban or rivaroxaban compared with …